Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.
about
In vivo interactions of continuous flucloxacillin infusion and high-dose oral rifampicin in the serum of 15 patients with bone and soft tissue infections due to Staphylococcus aureus - a methodological and pilot study.Development and validation of a liquid chromatography/tandem mass spectrometry method for the quantification of flucloxacillin and cloxacillin in microdialysis samples.Applications of minimal physiologically-based pharmacokinetic models.Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.Interethnic differences in pharmacokinetics of antibacterials.Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples.Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.Pulmonary Pharmacokinetics of Colistin Following Administration of Dry Powder Aerosols in Rats.The clinical relevance of plasma protein binding changes.Mechanism-based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model.Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.Fulminant peritonitis presumably caused by Panton-Valentine leukocidin-positive Staphylococcus aureus in a girl on peritoneal dialysis.Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensive Drug-resistant Pseudomonas aeruginosa.
P2860
Q33813070-7228ADD8-0E8E-4904-A703-76A4307463ADQ35233471-82814E62-5349-46F0-B769-25A9FA9CB599Q36517093-19701EA2-7EBE-473A-8B70-8CE08C6512FCQ37333151-FCF29EB6-712C-4E01-A277-4E55F3A4AE0EQ37538623-F5762593-4571-4D12-A55B-1F427CDEA750Q37818164-60A331ED-7449-4B42-B185-A7063813FBC7Q38266806-FD092EA7-346A-4F34-BA48-3FD2CA53AB55Q38369608-CDD63180-EC8A-48FD-907B-1C9E9154315FQ38896040-39D95BC1-73E7-4A1C-8719-33EBDD172AD2Q40093588-CE0125BF-45CD-4A14-8E1F-4F0CFF1C7123Q43830944-77B5455B-325D-43FE-9BDC-8B941479571FQ47273930-DFA2234E-CA1B-4665-B86A-DD047634FF32Q47656109-358A339A-B36B-4309-8E29-47DED4BDADE1Q47691167-06EFE40B-6842-476F-A775-068CC0711695Q47817710-CFC9BE70-C5D1-4EC2-9538-3C1ED979A4A4Q52597958-B9A74ADD-3847-428C-94F5-A4682AF39AEE
P2860
Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Population pharmacokinetics at ...... c profiling of flucloxacillin.
@ast
Population pharmacokinetics at ...... c profiling of flucloxacillin.
@en
type
label
Population pharmacokinetics at ...... c profiling of flucloxacillin.
@ast
Population pharmacokinetics at ...... c profiling of flucloxacillin.
@en
prefLabel
Population pharmacokinetics at ...... c profiling of flucloxacillin.
@ast
Population pharmacokinetics at ...... c profiling of flucloxacillin.
@en
P2093
P2860
P50
P356
P1476
Population pharmacokinetics at ...... c profiling of flucloxacillin.
@en
P2093
Carl M J Kirkpatrick
Fritz Sörgel
George L Drusano
Martina Kinzig-Schippers
P2860
P304
P356
10.1128/AAC.01410-06
P407
P577
2007-06-18T00:00:00Z